ISCT 2027: Cell and Gene Therapy's World Meeting Heads to Toronto

WHAT THIS ARTICLE COVERS

Each spring, the field of cell and gene therapy gathers for its largest global meeting, hosted by the International Society for Cell & Gene Therapy (ISCT). The 2027 edition is set for May 12–15 at the Metro Toronto Convention Centre, under the theme "Connecting Science to Medicine." This article explains what ISCT is, why its annual meeting is worth tracking for anyone following stem cell and cellular therapy research, and what readers can realistically expect to come out of it — without overstating what any single conference can deliver.

What ISCT Is, and Why It Carries Weight

ISCT was founded in 1992 and has grown into one of the most established professional societies in regenerative medicine. Its stated mission is "to drive clinical translation of cell and gene therapies worldwide," and it organizes its work around three pillars: academic research, regulatory science, and commercialization. That three-part focus is part of what makes the society distinctive — it isn't purely an academic club or purely an industry trade group. It pulls together the researchers discovering mechanisms, the regulators who decide what gets approved, and the companies trying to manufacture and scale therapies, in the same rooms.

Why the Annual Meeting Matters for Stem Cell Medicine

Recent ISCT annual meetings have drawn more than 3,000 participants from across the global cell and gene therapy field — clinicians, bench researchers, lab and manufacturing professionals, regulatory specialists, hospital transplant teams, supply-chain and health-economics experts, and investors. For a field like stem cell therapy, where hype often outpaces evidence, a meeting with this mix of audiences is genuinely useful: it's where manufacturing problems, regulatory sticking points, and early clinical data get discussed openly, rather than filtered through marketing. That matters for patients and caregivers trying to tell real progress from premature promotion, even if the sessions themselves are written for specialists.

What to Watch For in the Program

ISCT's recent meetings have typically built their agendas around a few recurring pillars, and past programs have included:

• A Translational Pathway Program tracking therapies from bench to bedside
• A Roundtable Program for focused discussion among specialists
• A Lab Practices Essentials Track aimed at manufacturing and quality standards
• Corporate and thought-leadership sessions on commercialization and investment

The exact 2027 Toronto agenda hadn't been published at the time of writing, so readers should check ISCT's own site closer to the date for confirmed tracks and speakers rather than assuming last year's structure repeats exactly.

Practical Details

The meeting runs May 12–15, 2027, in Toronto, Canada, with both in-person and virtual attendance options historically offered by ISCT (in-person registration has included access to the full program, exhibit and poster halls, and roundtable sessions, while virtual passes have offered a curated set of livestreamed and on-demand sessions). ISCT membership has typically carried a registration discount. Readers planning to attend, follow remotely, or simply track published abstracts afterward should watch ISCT's official 2027 Toronto meeting page for registration opening dates and the final program.

Bottom Line

ISCT 2027 is a real, substantial opportunity to see where stem cell and broader cell-and-gene therapy science actually stands — not through press releases, but through the unfiltered exchange between researchers, regulators, and manufacturers who have to make these therapies work in practice. It won't settle whether any specific experimental therapy is safe or effective; that still depends on the peer-reviewed data and regulatory review that gets discussed there. But for readers trying to separate genuine translational progress from overstated claims, a meeting of this scale and composition is one of the more reliable places to watch the field in real time.